

Bactericidal effects of snake venom phospholipases A2: a systematic review and analysis of minimum inhibitory concentration

Abdullahi, Zainab U.; Musa, Salihu S.; Abu-Odah, Hammuda; Ahmad, Ayman ; Lawan, Abdulmalik; Bello, Umar

Published in:
Physiologia

DOI:
[10.3390/physiologia3010003](https://doi.org/10.3390/physiologia3010003)

Publication date:
2023

Document Version
Publisher's PDF, also known as Version of record

[Link to publication in ResearchOnline](#)

Citation for published version (Harvard):
Abdullahi, ZU, Musa, SS, Abu-Odah, H, Ahmad, A, Lawan, A & Bello, U 2023, 'Bactericidal effects of snake venom phospholipases A2: a systematic review and analysis of minimum inhibitory concentration', *Physiologia*, vol. 3, no. 1, pp. 30-42. <https://doi.org/10.3390/physiologia3010003>

General rights







Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please view our takedown policy at <https://edshare.gcu.ac.uk/id/eprint/5179> for details of how to contact us.

Systematic Review

Bactericidal Effects of Snake Venom Phospholipases A2: A Systematic Review and Analysis of Minimum Inhibitory Concentration

Zainab Umar Abdullahi ^{1,2}, Salihu Sabiu Musa ^{3,4,*}, Hammoda Abu-Odah ^{5,6,7}, Ayman Ahmed ^{8,9}, Abdulmalik Ahmad Lawan ¹⁰ and Umar Muhammad Bello ^{11,*}

- ¹ Department of Biological Sciences, Federal University Dutsin-ma, Katsina 821101, Nigeria
 - ² Department of Biological Sciences, Bayero University, Kano 700006, Nigeria
 - ³ Department of Applied Mathematics, The Hong Kong Polytechnic University, Hong Kong SAR, China
 - ⁴ Department of Mathematics, Kano University of Science and Technology, Wudil, Kano 13101, Nigeria
 - ⁵ School of Nursing, The Hong Kong Polytechnic University, Hong Kong SAR, China
 - ⁶ Centre for Advancing Patient Health Outcomes, A JBI Affiliated Group, School of Nursing, The Hong Kong Polytechnic University, Hong Kong SAR, China
 - ⁷ Nursing and Health Sciences Department, University College of Applied Sciences (UCAS), Gaza 1415, Palestine
 - ⁸ Swiss Tropical and Public Health Institute (Swiss TPH), 4123 Allschwil, Switzerland
 - ⁹ Faculty of Science, University of Basel, Petersplatz 1, 40001 Basel, Switzerland
 - ¹⁰ Department of Computer Science, Kano University of Science and Technology, Kano 713281, Nigeria
 - ¹¹ Department of Physiotherapy and Paramedicine, Glasgow Caledonian University, Glasgow G4 0BA, UK
- * Correspondence: salihu-sabiu.musa@connect.polyu.hk (S.S.M.); umar.bello@gcu.ac.uk (U.M.B.)

Abstract: Background: Infections caused by multi-drug resistance (MDR) strains are potentially fatal public health issues worldwide that need pressing attention. Previous reports suggested using snake venom fractions as an effective alternative mechanism to the already available antibacterial drugs. In this study, we conducted a systematic review to analyze the bactericidal effects of snake venom phospholipases (PLA₂s). Methods: From the beginning through 30 March 2022, we searched the PubMed and Embase databases in accordance with the most recent PRISMA recommendations. We also conducted a manual search to identify relevant reports to improve literature coverage. Results: A total of 24 studies were included based on the selection criteria to compile this review. Of them, 16 studies were obtained from the abovementioned databases and eight through manual searches. The other 8 studies were obtained through the references of the included studies. According to the review, we reported that some PLA₂s showed more vigorous bactericidal activity on some Gram-negative and a moderate effect on Gram-negative and Gram-positive. Furthermore, we reported that the presence of p-bromophenacyl bromide (p-BPP) showed a significant decrease in enzymatic and associated antibacterial activities. Moreover, we observed that about 80% of the PLA₂s reported in our systematic review study were those from the Viperidae family, whereas 20% came from the Elapidae family. Moreover, some variations were revealed in the current study regarding the mechanism of actions of the snake venom PLA₂s (svPLA₂s). Conclusion: This systematic review provides a comprehensive overview of the bactericidal effect of snake venom PLA₂s and the analysis of the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of PLA₂s for bacterial strains. Varying bactericidal effects from various snake species and South American rattlesnakes were reported, presenting compelling concepts to the alternative search for therapies against bacterial resistance. Thus, further analysis of the bactericidal effects of other snake venoms PLA₂s considering different strains is needed. Moreover, more data are needed to investigate other bacteria of public health priority using peptides and other purified snake toxins.

Keywords: antimicrobial resistance; bactericidal effect; snake venoms; multi-drug-resistant; systematic review



Citation: Abdullahi, Z.U.; Musa, S.S.; Abu-Odah, H.; Ahmed, A.; Lawan, A.A.; Bello, U.M. Bactericidal Effects of Snake Venom Phospholipases A2: A Systematic Review and Analysis of Minimum Inhibitory Concentration. *Physiologia* **2023**, *3*, 30–42. <https://doi.org/10.3390/physiologia3010003>

Academic Editor: Philip J. Atherton

Received: 25 September 2022

Revised: 19 December 2022

Accepted: 30 December 2022

Published: 9 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Antimicrobial resistance is one of the most substantial risks to public health worldwide, including in developed countries in Europe [1]. According to the World Health Organization (WHO), infections caused by the multi-drug-resistant (MDR) strains are among the top ten reasons for mortality globally [2]. It is noteworthy that evidence about the development and spread of antibiotic-resistant bacteria is increasingly growing [3]. Furthermore, previous investigation has demonstrated that the improper use of antibiotics, such as vancomycin, can result in the development of vancomycin-intermediate (VISA) and vancomycin-resistant strains of bacteria such *Enterococci* [4]. Similarly, various bacteria, including *Pseudomonas*, *Klebsiella*, *Enterobacter*, *Acinetobacter*, and *Salmonella*, can resist several antibiotics [5]. Thus, laboratory- and clinical-based research geared toward discovering new and potent bactericidal candidates with unique mechanisms of action that could overcome antimicrobial resistance is warranted.

Studies on crude snake venoms and/or their fractions often result in potential therapeutic molecules against bacteria and other parasites [6]. Snake venoms are composed of a spectrum of protein-based constituents. These components could be categorized into four broad groups [6], namely: (1) The dominant group, which consists of the three-finger toxins (3FTx), phospholipases A2 (PLA₂), snake venom metalloproteases (SVMP), and snake venom serine proteases (SVSP), (2) The second group consists of a small number of proteins, which includes Kunitz peptides (KUN), cysteine-rich secretory proteins (CRiSP), L-amino acid oxidases (LAAO), C-type lectins (CTL), disintegrins (DIS), and natriuretic peptides (NP), (3) The third group contains the rarely observed snake venom proteins, including venom nerve growth factor (VNGF), vascular endothelial growth factor (VEGF), acetylcholinesterases, hyaluronidases, 5'-nucleotidases, phosphodiesterases (PDE), and snake venom metalloprotease inhibitors, and (4) finally, the fourth group includes cobra venom factors (CVF), galactose-binding proteins, aminopeptidases, and waprins.

However, the proteins mentioned above may only be readily available in some venomous snakes. For instance, elapids snakes have Group I PLA₂s and 3FTx, whereas the mambas are known to consist mainly of Kunitz peptides that are also known as dendrotoxins. The viperids consist of PLA₂s and proteases as the most abundant protein groups with varying quantities of serine proteases and metalloproteases [7].

In this study, we present a thorough review based on the existing literature on the bactericidal effect of snake venom PLA₂s, alongside an analysis of the given minimal inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) against the bacterial strains listed under the study, highlighting the potential of snake venom fraction as promising candidates against several species of antimicrobial resistant bacteria.

2. Methods

2.1. Search Strategy

Relevant studies that reported the bactericidal effects of PLA₂s were searched from PubMed and Embase databases from inception until 30 March 2022. We utilized the search terms (“Bactericidal OR bacterial effect OR Antibacterial”) and (“Snake Venom PLA₂s OR Venomous snake PLA₂ OR Snake Venom Peptides OR Snake venom Components OR Fractions OR Enzymes OR Proteins”). The outcome of the searches from the two terms was then combined using the Boolean operator ‘AND’. We conducted a manual search of the literature to ensure more comprehensive coverage of the studies in the area of research. Reference lists of included articles that met eligibility criteria were also manually searched to identify any additional articles.

2.2. Eligibility Criteria

We included only original articles published in the English language that reported the bactericidal effect of snake venom PLA₂s in our review. The study excluded reviews, articles on bactericidal effects of snake venoms’ fractions other than PLA₂s, those published in a language other than English, and studies that employed the use of commercial venoms

in which the snake specie information was not mentioned, as well as studies involving the effects of venoms on other parasites instead of bacteria.

2.3. Study Selection, Data Extraction and Data Synthesis

PRISMA systematic review procedure was utilized in the process of selecting the most relevant articles to be included in the study [8]. To avoid any potential bias in the search and/or inclusion of studies, two authors (ZUA and SSM) conducted the article screening processes at the title, abstract, and full-text phases. The same authors conducted the extraction of relevant data for the review. A customized excel sheet was used for the data extraction. Any disagreements during the article screening processes and the data extraction were resolved and discussed with all the other authors and then agreed upon by consensus. Data extracted included authors' names, date of publication, snake species, PLA₂s, bacterial isolates, minimum inhibitory concentration, minimum bactericidal concentration, and activities of PLA₂s on the tested bacteria. The synthesis of the extracted data was guided by the "synthesis without meta-analysis" (SWIM) protocol [9].

3. Results

3.1. Search Results

We retrieved 223 reports from searching the databases, 91 and 124 were from PubMed and Embase, respectively. Furthermore, additional eight studies were identified manually through the search of the references of the included studies. After removing all duplicates and the screenings at the titles and abstract phases, the remaining articles were considered for further screening, which led to the exclusion of 163 unrelated articles as well as 17 duplicates. Furthermore, we examined the full texts of the remaining 43 articles, from which 19 studies were excluded (Figure 1). Finally, twenty-four studies met the eligibility criteria and were included. Furthermore, additional eight studies were identified manually through the search of the reference lists, totaling the included reports in this study 26. Table 1 lists the distinguishing features of the included studies, and Figure 1 shows the flowchart of the research search and screening procedures. Moreover, the summary data for MIC and MBC, as well as sequence data for the PLA₂s extracted from the included studies, are provided in Table 2.

Table 1. Features of the analyzed studies.

Study	Snake Specie(s)	PLA ₂ s	Bacterial Specie(s)	Activity on Bacterial Strains
Nunes et al. [5]	<i>Bothrops Erythromelas</i>	BE-I- PLA ₂	<i>Acinetobacter baumannii</i> , <i>Staphylococcus aureus</i> , <i>Escherichia coli</i>	Showed bactericidal activity against <i>S. aureus</i> and antibiofilm activity against <i>A. baumannii</i> .
Sudarshan et al. [10]	<i>Naja naja</i>	PLA ₂ (NN-XIb-PLA ₂)	<i>S. aureus</i> , <i>Bacillus subtilis</i> , <i>E. coli</i> , <i>Vibrio cholera</i> , <i>Klebsiella pneumonia</i> , <i>Salmonella typhi</i>	Inhibited the growth of all isolates, but more active on <i>S. aureus</i> and <i>B. subtilis</i> .
Alves et al. [11]	<i>Crotalus durissus terrificus</i>	Crotoxin PLA ₂ -Crotoxin B	<i>Ralstonia solanacearum</i>	PLA ₂ -CB showed 52% growth inhibition.
Vargas et al. [12]	<i>Porthidium masutum</i>	PnPLA ₂	<i>E. coli</i> (ATCC 25922), <i>S. aureus</i> (ATCC 25923)	Showed bactericidal activity against <i>S. aureus</i> in a dose-dependent manner but not on <i>E. coli</i> .
Samy et al. [13]	<i>Echiscarinatus</i>	PLA ₂ -EcTx-I	<i>Bulholderia pseudomallei</i> (KHW and TES), <i>Enterobacter aerogenes</i> , <i>E. coli</i> , <i>Proteus vulgaris</i> , <i>P. mirabilis</i> , <i>P. aeruginosa</i> , <i>S. aureus</i>	Strong bactericidal activity was observed in <i>B. pseudomallei</i> (KHW) and <i>E. aerogenes</i> . It showed only moderate effect on other bacteria.
Sudarshan et al. [14]	<i>Daboia russelliipulchella</i>	PLA ₂ fraction V (VRV-PL-V)	<i>S. aureus</i> , <i>B. sub</i> , <i>E. coli</i> , <i>V. cholerae</i> , <i>K. pneumoniae</i> , <i>S. paratyphi</i>	Exhibited bactericidal activity against <i>S. aureus</i> and <i>B. subtilis</i> more than on <i>E. coli</i> , <i>V. cholerae</i> , <i>K.pneumoniae</i> , <i>S. paratyphi</i>
Torres et al. [15]	<i>B. marajeensis</i>	BmarPLA ₂	<i>P. aeruginosa</i> , <i>S. aureus</i>	Could not promote any inhibitory activity
Samy et al. [16]	<i>C. adamanteus</i>	PLA ₂ -CaTx-II	<i>S. aureus</i> , <i>B. pseudomallei</i> (KHW), <i>B. pseudomallei</i> (TES), <i>E. coli</i> , <i>K. pneumoniae</i> , <i>Streptococcus pneumoniae</i> , <i>P. vulgaris</i> , <i>P. aeruginosa</i> , <i>E. aerogenes</i>	Resulted in bactericidal effect by forming pores and damaging the cell wall membrane of the bacterial isolates.

Table 1. Cont.

Study	Snake Specie(s)	PLA ₂ s	Bacterial Specie(s)	Activity on Bacterial Strains
Jia et al. [17]	<i>Agkistrodon piscivorusleucostoma</i> ,	PLA ₂	<i>B. subtilis</i> , <i>S. aureus</i> , <i>E. coli</i> , <i>V. cholera</i>	<i>A. pleucostoma</i> PLA ₂ proteins namely AplAsp49 and AplLys49 did not show any bactericidal activity against any of the bacterial isolates.
Samy et al. [18]	<i>A. halys</i>	PLA ₂ - AgkTX-II	<i>S. aureus</i> , <i>P. vulgaris</i> , <i>P. mirabilis</i> , <i>B. pseudomallei</i> , <i>E. coli</i> , <i>E. aerogenes</i> , <i>B. pseudomallei</i> (TES and KHW), <i>P. aeruginosa</i>	Caused potent bactericidal activity against <i>S. aureus</i> , <i>P. vulgaris</i> , <i>P. mirabilis</i> , and <i>B. pseudomallei</i> with rapid killing effect on <i>S. aureus</i> , <i>P. vulgaris</i> , <i>B. pseudomallei</i> in a dose dependent pattern. It was suggested that the activity was through membrane permeability and damage.
Samy et al. [19]	<i>C. durissuterrificus</i> , <i>Vipera ammodytes ammodytes</i> , <i>C. scutulatusscutulatus</i> , <i>Bungarusmulticinctus</i> , <i>Oxyuranus scutellatusscutellatus</i> , <i>Pseudechis australis</i> , <i>D. russelli</i>	C.d.t- CA C.d.t-CB V.a.a-a C.s.s-m B.m- β-b O.s.s-t P.a-m D.r-d	<i>B. pseudomallei</i> (KHW), <i>B. pseudomallei</i> (TES)	Presented bactericidal activity which was incriminated to be due to activity of cytotoxin and the PLA ₂ .
Samel et al. [20]	<i>N. oxiana</i> , <i>Viperalebetina</i> , <i>V. berusberus</i>	NNOPLA ₂ VLPLA ₂ VBBPLA ₂	<i>B. subtilis</i> , <i>E. coli</i> , <i>Vibrio fishera</i> , <i>S. aureus</i>	Only VBBPLA ₂ from <i>V. berusberus</i> completely inhibited the growth of <i>B. subtilis</i> . Moreover, the effect of VBBPLA ₂ was reported to be due to other properties of the protein rather than catalytic activity. To <i>S. aureus</i> , NNOPLA ₂ (from <i>Najanaja</i>) inhibited its growth and resulted in just a slight inhibition of the growth of <i>B. subtilis</i> . However, none of the three svPLA ₂ s showed inhibitory effect on <i>E. coli</i> even at the highest concentration tried.
Roberto et al. [21]	<i>B. jararacussu</i>	BthA-I-PLA ₂	<i>E. coli</i> (ATCC 29648) <i>S. aureus</i> (ATCC 25923)	Presented bactericidal activity against both bacteria.
Xu et al. [22]	<i>Bungarusfasciatus</i>	BPFA-PLA ₂	<i>E. coli</i> , <i>S. aureus</i>	Showed activity against both bacteria.
Corrêa et al. [23]	<i>B. neuwiediurutu</i>	BnuTX-I PLA ₂	<i>E. coli</i> (ATCC 25922), <i>S. aureus</i> (ATCC 29213), <i>K. pneumoniae</i> (ATCC 13883) <i>P. aeruginosa</i> (ATCC 27853)	Showed bactericidal activity against both Gram-positive and Gram-negative isolates, with greatest inhibitory effect on <i>P. aeruginosa</i> .
Denegri et al. [24]	<i>B. alternatus</i>	Ba SpII RP4- PLA ₂	<i>S. aureus</i> (ATCC 25923), <i>E. coli</i> (ATCC 25922)	Showed no bactericidal activity against the two bacteria.
Abid et al. [25]	<i>Walterinnesia aegyptia</i>	WaPLA ₂ -I WaPLA ₂ -II	<i>B. subtilis</i> (ATCC 6633), <i>B. cereus</i> (ATCC 14579), <i>E. faecalis</i> (ATCC 29122), <i>S. aureus</i> (ATCC 25923), <i>S. epidermis</i> (ATCC 14990), <i>E. coli</i> (ATCC 25966), <i>K. pneumoniae</i> (ATCC 700603), <i>P. aeruginosa</i> (ATCC 27853), <i>Salmonella enterica</i> (ATCC 43972)	WaPLA ₂ -I presented bactericidal activity against all the gram positive and negative bacteria with the highest activity recorded from <i>E. coli</i> , <i>S. enteric</i> and <i>S. aureus</i> . Lower WaPLA ₂ -II bactericidal effect was recorded from <i>P. aeruginosa</i> . Notably, <i>E. faecalis</i> , <i>S. epidermis</i> , <i>S. aureus</i> , <i>E. coli</i> and <i>S. enteric</i> showed more sensitivity to WaPLA ₂ -II than to WaPLA ₂ -I. Using agar dilution method to determine IC ₅₀ , WaPLA ₂ -II presented an IC ₅₀ of 9 ± 0.2 to 20 ± 1 µg/mL against the human pathogenic strains whereas WaPLA ₂ -I presented 10 ± 0.3 and 17 ± 1.4 µg/mL. Noteworthy is that, WaPLA ₂ -II was more effective than WaPLA ₂ -I against <i>S. epidermis</i> , <i>E. coli</i> , <i>P. aeruginosa</i> , and <i>S. enteric</i> .
Barbosa et al. [26]	<i>B. jararacussu</i>	BthTX-I BthTX-II	<i>Xanthomonas axonopodispv.passiflorae</i>	Both PLA ₂ presented bactericidal activity against Gram-negative bacteria.
Shebl et al. [27]	<i>B. arietans</i> , <i>N. naja</i> , <i>C. cerastes</i> , <i>P. australis</i> , <i>N. nigricolis</i> , <i>V. lebetina</i> , <i>E. carinatus</i>	PLA ₂ s	<i>S. aureus</i> <i>E. coli</i> <i>S. typhimurium</i> <i>P. aeruginosa</i>	The highest PLA ₂ activity was identified in <i>B. arietans</i> , <i>P. australis</i> , <i>N. naja</i> and <i>N. nigricolis</i> . Moderate effect was recorded from <i>V. lebetina</i> and <i>C. cerastes</i> . <i>N. haje</i> presented the least activity.
Almeida et al. [28]	<i>C. oreganusabyssus</i>	CoaTX-II	<i>P. aeruginosa</i> (31NM) <i>E. coli</i> (ATCC 25922) <i>S. aureus</i> (BEC 9393) <i>S. aureus</i> (Rib1)	Presented bactericidal activity against <i>P. aeruginosa</i> , <i>E. coli</i> , MRSA <i>S. aureus</i> (Rib1 and BEC9393).

Table 1. Cont.

Study	Snake Specie(s)	PLA ₂ s	Bacterial Specie(s)	Activity on Bacterial Strains
Toyama et al. [29]	<i>C. durissusterrificus</i>	F15	<i>X. axonopodis.pv.passiflorae</i> , <i>Claribacter michiganensis michiganensis</i>	Reduced the bactericidal activity of <i>X. axonopodis.pv.passiflorae</i> by up to 58.2% and that of <i>C. michiganensis michiganensis</i> by up to 98%.
Bacha et al. [30]	<i>Walterinnesiaegyptia</i>	WaPLA ₂	<i>B. cereus</i> , <i>B. subtilis</i> , <i>E. faecalis</i> , <i>S. epidermis</i> , <i>S. aureus</i> , <i>E. coli</i> , <i>K. pneumoniae</i> , <i>P. aeruginosa</i> , <i>S. enteric</i>	Presented highly significant bactericidal activity against all Gram-positive and Gram-negative strains <i>B. cereus</i> , <i>B. subtilis</i> , <i>E. faecalis</i> , <i>S. epidermis</i> , <i>S. aureus</i> , <i>E. coli</i> , <i>K. pneumoniae</i> , <i>P. aeruginosa</i> , <i>S. enteric</i> .
Santamaría et al. [31]	<i>B. asper</i> , <i>Bothriechis schlegelii</i> , <i>Cerrophidion godmani</i> , <i>Atropoides nummifer</i>	<i>B.a-</i> myt- I, II and III <i>B. s-</i> myt I, <i>C.g-</i> myt- I, II, <i>A.n-</i> myt- I <i>B.a-spo-</i> myt- II	<i>S. typhimurium</i> , <i>S. aureus</i> , <i>Brucella abortus</i>	The eight PLA ₂ mytoxinsincludingL ys49 and Asp49-type isoforms presented bactericidal effect, with an indication that the activity could be due to group IIA PLA ₂ protein family. In vitro assay for bacterial, cytolytic, and anti-endotoxic effects of the peptides implies a correlation between the number of tryptophan substitutions presented and microbicidal potency, against <i>S. typhimurium</i> and <i>S. aureus</i> .
Costa et al. [32]	<i>B. brazili</i>	MTX-I MTX-II	<i>E. coli</i> (ATCC 29648)	Showed bactericidal effect.

Abbreviations: s. p. o = short peptide of *D. russelli*, B. a-myt- = *B. asper* myotoxin, B.s-myt = *B. schlegelii* myotoxin, C. g-myt = *C. godmani* myotoxin, a. m-myt = *A. nummifer* myotoxin.




Figure 1. PRISMA diagram for the study search and selection processes.

Table 2. Summary table for MIC, MBC, and sequence data extracted from the included studies.

Author	Minimum Inhibitory Concentration(s) (MIC)	Minimum Bactericidal Concentration (MBC)	PLA ₂ Sequence Data
Nunes et al. [5]	NA	NA	SLVQFETLIMKIAGRSGVWYYGSYGCYCGSG
Sudarshan et al. [10]	26.1 ± 3 µg/mL	NA	NA
	21.3 ± 2 µg/mL		
	23.3 ± 3 µg/mL		
	25.1 ± 1 µg/mL		
	19.3 ± 3 µg/mL		
	21.4 ± 2 µg/mL		
Alves et al. [11]	NA	NA	NA
Vargas et al. [12]	32 µg/mL	32 µg/mL	DLLQF-DMMKCC
	DPIA	DPBA	
Samy et al. [13]	DPIA	DPBA	SVVELGKMIIQETGKSPFPSYTSYGCFCCG (N) SLEELGKMILQETGKMPSKSYGAYGCNCGVLGR
	120 µg/mL	18 µg/mL	
	60 µg/mL	26 µg/mL	
	60 µg/mL	25 µg/mL	
	30 µg/mL	2 µg/mL	
	60 µg/mL	9 µg/mL	
	15 µg/mL	1 µg/mL	
	60 µg/mL	22 µg/mL	
Sudarshan et al. [14]	13 ± 2 µg/mL	NA	NA
	12 ± 3 µg/mL		
	15. ± 1 µg/mL		
	12. ± 2 µg/mL		
	14. ± 3 µg/mL		
	12 ± 3 µg/mL		
	13 ± 1 µg/mL		
Torres et al. [15]	DPIA	DPBA	SLEELGKMILQETGKMPSKSYGAYGCNCGVLGR
Samy et al. [16]	7.8 µg/mL	7.8–15.6 µg/mL	NA
	7.8 µg/mL	7.8–15.6 µg/mL	
	15.6 µg/mL	7.8–15.6 µg/mL	
	62.5 µg/mL	NA	
	250 µg/mL	NA	
	31.25 µg/mL	NA	
	62.5 µg/mL	NA	
	31.25 µg/mL	NA	
125 µg/mL	NA		
Jia et al. [17]	DPIA	DPBA	<i>Apl Lys49</i> = KK-YKA YFKLKCKK <i>Apl Asp49</i> = SKTYWK YPKKNCKE
Samy et al. [18]	10.63 µM	NA	HLLQFRKMIKKMTGKEPVVSYAFYGCYCGSGGRGKPKD
	21.25 µM		
	21.25 µM		
	85 µM		
	42.5–85 µM		
	21.25 µM		
	(KHW)—10.63 µM		
85 µM			

Table 2. *Cont.*

Author	Minimum Inhibitory Concentration(s) (MIC)	Minimum Bactericidal Concentration (MBC)	PLA ₂ Sequence Data
Samy et al. [19]	Cdt-Cb and CDt-Ca 0.5–0.03125 mg/mL	NA	NA
	Cb and Dt- 0.5–0.03125 mg/mL		
	V.a-aa, Cs- m, Bm-β-b, P.a-m, O. sst, D.r-d = DPIA		
Samel et al. [20]	NA	NA	NA
Roberto et al. [21]	NA	NA	MRTLWIMAVLLVGVESLWQ
Xu et al. [22]	NA	NA	MNPAHLLVLLAVCVSLGAA
Corrêa et al. [23]	NA	NA	SLFELGKMILQETGKNPPAKSYGAYGCNCGVLGRGPKD ATDRCC
Denegri et al. [24]	NA	NA	DLLQFEGMLKIAGKSGFWYYGAYGCYCGAGGQCTPVDA TDRCCQVHDCCYKKTNCN
Abid et al. [25]	NA	NA	NLQFGMIKLTGKPEALSYNAYCGWGGQKPDATDHC CFVHDCC
Barbosa et al. [26]	NA	NA	NA
Shebl et al. [27]	B.a—NA P.a—625 µg/mL N.g—NA N.n.n—625 µg/mL V.l—NA E.c—NA C.c—1250 µg/mL	NA	NA
	B.a—312.5 µg/mL P.a—156 µg/mL N.g—312.5 µg/mL N.n.n—156 µg/mL V.l—625 µg/mL E.c—625 µg/mL C.c—625 µg/mL		
	B.a—NA P.a—312.5 µg/mL N.g—625 µg/mL N.n.n—312.5 µg/mL V.l—625 µg/mL E.c—1250 µg/mL C.c—1250 µg/mL		
	B.a—NA P.a—NA N.g—1250 µg/mL N.n.n—1250 µg/mL V.l—NA E.c—NA C.c—NA		
Almeida et al. [28]	NA	NA	SLVELGKMILQETGKNAIPSYGFYGCNCGWGGRGKPKDA TDRCCFVHKCC
Toyama et al. [29]	NA	NA	HLLQFNKMIKFETRKNVAPFYAFYGCYCGWGGQRRPKD ATDRCCFVHDCCYGKLTCKNTKWDIYRSLKSGYITCGK GTWCKEQICECDRVAECLRRSLSTYKNEYMFYPKSR CRRPSETC

Table 2. Cont.

Author	Minimum Inhibitory Concentration(s) (MIC)	Minimum Bactericidal Concentration (MBC)	PLA ₂ Sequence Data
Bacha et al. [30]	>9 µg/mL	NA	NLYQFKNMVQCVGTQLCVAYVKYGCYCGPG
	>12 µg/mL		
	>7 µg/mL		
	>12 µg/mL		
	>5 µg/mL		
	>7 µg/mL		
	>8 µg/mL		
	>10 µg/mL		
Santamaría et al. [31]	NA	NA	KKWRWWLKALAKK
Costa et al. [32]	NA	NA	MTX-I = SLWEFGQMIKETGKLPFPYGYGAYGCYCGWGRRGPK-DATDRCCYVHDC
			MTX-II = SLFQLGKMILQETGKNPAASYGAYGCNCGVLGRGKPK-DATDRCCYVHKC

Abbreviations: NA = not available, DPIA = did not promote inhibitory activity, DPBA = did not promote bactericidal activity, C.d.t CB = *C. dirussus terrificus* CrotoxinB, C.d.t CA = *C. dirussus terrificus* Crotoxin A, V. a-aa = *V. ammodytes* ammodytoxin, Cs-m = *C. scutulatus* mojave toxin, Bm-β-b = *B. multicinctus* β-bungarotoxin, P.a-m = *P. australis* mulga toxin, O. sst = *O. scutellatus* taipoxin, D. r-d = *D. russelli* daboia toxin.

3.2. Bactericidal Effects of Snake Venom PLA₂s

Snake venom PLA₂s (svPLA₂s) are enzymatic proteins with low molecular weights. They catalyze the hydrolysis of the 3-sn-phosphoglyceride-dependent calcium 2-acyl ester bond, yielding lysophospholipids and fatty acid products [6]. Snake venom PLA₂s have similar toxicological profiles, including cytotoxicity, myotoxicity, oedema, inflammation, neurotoxicity, hypotension, anticoagulant activity, hemolysis, hyperalgesia, and microbicidal activity [5]. Some of the evaluated PLA₂s (either acidic or basic) could present an IC₅₀ against at least Gram-positive or Gram-negative bacteria, whereas others could not show any activity against any strain. Nunes et al. [1] reported that the acidic PLA₂ from *B. erythromela* presented IC₅₀ against Gram-positive bacteria but not negative bacteria. Torres et al. [15] reported that the basic PLA₂ isolated from *B. marajeonsis* showed no inhibitory effect on neither *P. aeruginosa* or *S. aureus*.

Moreover, Jia et al. [17] reported that the PLA₂ from *Agkistrodon piscivorus leucostoma*, AplAsp49, and AplLys49, presented no bactericidal effect against any of the bacterial strains. Moreover, Sudarshan et al. [10] reported that the basic PLA₂ of *D. russelliipulchella* showed higher bactericidal activity against Gram-positive bacteria when compared with Gram-negative bacteria. It has been reported that the bactericidal activity of PLA₂, especially the basic is related to the disturbances of bacteria membrane integrity [23]. Gram-negative bacteria have a cell wall that is made up of an inner membrane formed of phospholipids, an outer membrane made of asymmetric lipids, and a layer of peptidoglycans. This structure acts as a barrier to medications that have been established. A similar scenario exists for the PLA₂, as the outer membrane naturally resists its activity [33]. On the other hand, Gram-positive bacteria possess just one layer of peptidoglycans and then an internal cell membrane, showing their prompt susceptibility to the action of PLA₂. As such, the low bactericidal activity of some PLA₂s in Gram-negative bacteria compared with Gram-positive bacteria could be due to the difference in the structure of their respective cell walls. Sudarshan et al. [10] reported that there was a strong, established relationship between the hemolytic and bactericidal activity of *D. russelliipulchella* PLA₂.

Furthermore, it was reported that p-bromophenacyl bromide (p-BPP) presents a significant decrease in enzymatic activity and associated antibacterial activities, thereby

destabilizing the membrane bilayer. Regarding PLA₂ crotoxin A or B (PLA₂- CA and PLA₂- CB), Alves et al. [11] reported that both from *C. durissus terrificus* showed high bactericidal activity against *R. solanacearum*. Similarly, Samy et al. [19] reported that crotoxin B of *C. durissus terrificus* and daboia toxin of *Daboia russelli* presented the most robust bactericidal activity against the two strains of *B. pseudomallei* (TES and KHW). Some PLA₂s were reported to have shown bactericidal activity against both Gram-positive and Gram-negative bacteria [16,31]. Others presented a bactericidal effect on Gram-positive and not Gram-negative bacteria [12]. Of interest to note is that some PLA₂ showed more vigorous bactericidal activity on some Gram-negative bacteria and moderate on other Gram-negative and Gram-positive bacteria [13].

3.3. Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) for Bacterial Strains

Minimum inhibitory concentrations (MICs) are the lowest concentration of an antimicrobial that could inhibit the visible growth of a microorganism after overnight incubation. MICs are utilized by diagnostic laboratories mainly to confirm resistance but are most often used as a research tool to determine the in vitro activity of new antimicrobials [34]. In the works of Samy et al. [13] and Samy et al. [16], Vargas et al. [12], and Jia et al. [17], broth micro-dilution assay was employed. The procedure entails suspending fresh overnight bacterial cultures to a turbidity of 0.5 McFarland units and further subjecting them to a dilution in Mueller Hinton (MH) and tryptic soy (TS) broth, followed by a dilution to approximately 1.5×10^5 – 3.2×10^6 CFU/mL (CFU = colony forming unit). On the other hand, minimum bactericidal concentration (MBC) is referred to as the minimum bactericidal density required to kill bacteria; as such, it is opposed to mere bacteriostatic densities [35]. According to Samy et al. [13] and Samy et al. [16], the plating technique was carried out whereby the broth from the MICs well and those from above the wells were plated for each bacterial strain 3.2×10^6 CFU/mL onto approximate drug-free growth media MH and TS agar plates used for determining antibacterial activity. Surviving bacteria were then quantified using the dilution plate technique. On the starting inoculums, the quantitative colony counts were assessed. The lowest concentration that killed up to $\geq 99.9\%$ of the starting inoculums was defined as the MBC. In the work of Jia et al. [17], the plating technique involved adding two hundred microliters of 1/1000 diluted overnight bacterial cultures to 1 mg/mL, 0.75 mg/mL, 0.1 mg/mL 50 μ g/mL 25 μ g/mL, 10 μ g/mL PLA₂ in the 96-well plates in parallel 50 μ g/mL of the control (antibiotic), and PLA₂ buffer as a negative control. Bacterial cultures that presented no growth were then plated on agar and incubated overnight to achieve colony-forming unit (CFU) enumeration.

4. Discussion

Overall, our systematic search identified 24 articles on the bactericidal effect of svPLA₂s. The majority of the studies (80%) found through the search were on the PLA₂s of snakes from the Viperidae family, whereas 20% were on the PLA₂s from snakes of the Elapidae family. There are considerable variations in the composition of snake venoms recorded even from closely related species and within species [6]. Evidence of intra-genus or intra-specific variation in venom compositions has been documented in pit vipers and adders [36]. This variation was attributed to diet [37] or topography [38]. Repeated toxin-encoding genes, production processes, as well as functional and structural diversifications are other attributable factors [39]. For instance, the sea snake *Laticauda semifasciata* *S. venom* has a simple composition, with only two prominent protein families, the 3FTxs and the PLA₂s. However, about 50–100 peptides or proteins representing about 10–20 protein families are present in the venoms of rattlesnakes and mambas [7]. In general, cobra, kraits, and the hydrophids particularly have more negligible toxins such as 3FTxs and PLA₂, whereas the venoms of vipers are composed of the more significant fractions with enzymatic roles such as snake venom metalloproteinase and snake venom serine protease [7]. For instance, amino acids, small peptides, carbohydrates, lipids, biogenic amines, and enzymes are

contained in the venom of *C. durissus terrificus*, whereas that of *B. jararaca* is composed of peptides serine and metalloproteases [40]. As such, the activity of snake venoms varies due to differences in concentrations and compositions.

It has been reported that svPLA₂s makes a considerable component of the venoms of the vipers and elapids [41] due to their biomedical importance over the other compositions of snake venoms [42]. They are proteins that belong to groups I and II. The group I PLA₂s are those of snakes from the Elapidae family (Elapidae and Hydrophiinae) [7]. In contrast, those belonging to group II are from snakes of the Viperidae family (Viperinae and Catalina) [7]. The latter comprises two subgroups: the catalytically active Asp49-PLA₂ and the catalytically inactive PLA₂ homologs containing Lys49 residue [43]. The GIIA PLA₂s were reported to have an essential role in the defense against bacteria. The ASP49- PLA₂ and LYS49- PLA₂ homologs were reported to have acted synergistically, increasing Ca²⁺ ions in the plasma membrane, resulting in the rapid death of myotubes [43].

Crotoxin is a non-covalent heterodimeric neurotoxin of two subunits; an active PLA₂ and a chaperone peptide called crotoxin. The molecule has three peptide chains connected by seven disulfide bridges [44]. It is the main neurotoxin in the venom of the South American rattlesnake (*C. durissus terrificus*) and accounts for about 50% of its dry weight and it acts at the presynaptic membrane level. Pharmacologically, crotoxin promotes pre- and post-synaptic effects, indicating several interactions with excitable cells [29]. Crotoxin B, a basic neurotoxic phospholipase A, has three chain proteins that promote the lethal potency of crotoxins [19]. In contrast, crotoxin A (CA) is the acidic subunit of the crotoxin (Ctx) on which the essential subunit crotoxin B (CB) depend for the ability to bind specifically to the cell membrane [45].

There are variations in the mechanism of actions of svPLA₂s. For instance, CaTx-II from *C. adamanteus* was reported to have inhibited the growth of *E. aerogenes* through the disintegration of its cell wall by generating pores in the membrane. Furthermore, the protein has been reported to promote the healing of wounds [16]. It is noteworthy that peptides produced by the breakdown of svPLA₂ can interact with lipopolysaccharide (LPS), specifically, the lipid A component of *S. aureus*, causing membrane permeabilization and acting as a bactericide [16]. Various cationic peptides from *B. asper*'s svPLA₂s exhibit bactericidal activity against *K. pneumoniae*, protect mice from *S. enterica*-induced peritonitis, and cause membrane permeabilization in *S. aureus* when they are derived from cationic peptides [31,46,47]. The derivatives of the carboxy terminus of svPLA₂s found in these peptides, which range from ten to twenty-two amino acids, are crucial. Compared to the parent compounds, they are less toxic to eukaryotic cells and have greater bactericidal activity. Similarly, it has been documented that the C-terminal cationic/hydrophobic segment (residues 115–129) of svPLA₂s has bactericidal potential. As such, identifying bactericidal positions in svPLA₂s because of developing new therapeutics is promising [48–50]. Furthermore, there have been reports of varying MICs and MBCs against various bacterial strains, as well as sequence data of each PLA₂.

4.1. Strength

Our systematic review has the following strengths; firstly, we conducted a thorough and extensive search of literature via PubMed and Embase databases, as well as a manual search of the literature, which enriched our search coverage. Secondly, we adopted appropriate quality rating tools for assessing the qualities of the included studies.

4.2. Limitations

The study is associated with some limitations that should be considered when interpreting the reported findings. Firstly, we excluded studies based on language (only those published in English), thereby limiting the ability to incorporate relevant data from studies in languages other than English. Moreover, most of the included studies did not include information on accession numbers. However, we have included the sequence information found from each study in our work to have representative information for at least each

included study. Nevertheless, in our future research, we will deeply investigate the DNA sequence of PLA₂ with nucleotide accession numbers when the data become available.

5. Conclusions

This systematic review provides a comprehensive overview of the bactericidal effect of snake venom PLA₂s and analyses the minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of PLA₂s for bacterial strains. Varying bactericidal effects of various PLA₂s were reported, presenting compelling concepts to the alternative search for therapies against bacterial resistance. However, more data are needed to investigate the bactericidal effects of other snake venoms PLA₂s using purified snake toxins. Thus, it is imperative to study other bacteria of public health importance using snake venoms and their associated purified snake toxins.

Author Contributions: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing—original draft, Z.U.A.; conceptualization, data curation, formal analysis, investigation, methodology, project administration, resources, validation, visualization, writing—original draft, writing—review and editing, S.S.M.; conceptualization, formal analysis, investigation, methodology, validation, writing—review and editing, supervision, H.A.-O.; formal analysis, investigation, methodology, validation, writing—review and editing, A.A.; formal analysis, investigation, methodology, validation, writing—review and editing, A.A.L.; Conceptualization, formal analysis, investigation, methodology, validation, visualization, writing—original draft, writing—review and editing, U.M.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All data used in this work are in the publicly domain.

Acknowledgments: The authors are appreciative to the handling editor and the unanimous reviewers for their insightful observations, which helped us to enhance the manuscript.

Conflicts of Interest: All authors declared no conflict of interest.

References

1. Bocian, A.; Hus, K.K. Antibacterial properties of snake venom components. *Chem. Pap.* **2020**, *74*, 407–419. [CrossRef]
2. World Health Organizations. Antimicrobial Resistance. Key Facts. 2022. Available online: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance> (accessed on 11 March 2022).
3. Fair, R.J.; Tor, Y. Antibiotics and bacterial resistance in the 21st century. *Perspect Med. Chem.* **2014**, *6*, 25–64. [CrossRef] [PubMed]
4. Cázares-Domínguez, V.; Cruz-Córdova, A.; Ochoa, S.A.; Escalona, G.; Arellano-Galindo, J.; Rodríguez-Leviz, A.; Hernández-Castro, R.; López-Villegas, E.O.; Xicohtencatl-Cortés, J. Vancomycin tolerant, methicillin-resistant *Staphylococcus aureus* reveals the effects of vancomycin on cell wall thickening. *PLoS ONE* **2015**, *10*, e0118791. [CrossRef] [PubMed]
5. Nunes, E.; Frihling, B.; Barros, E.; de Oliveira, C.; Verbisck, N.; Flores, T.; de Freitas Júnior, A.; Franco, O.; de Macedo, M.; Migliolo, L.; et al. Antibiofilm activity of acidic phospholipase isoform isolated from *Bothrops erythromelas* snake venom. *Toxins* **2020**, *12*, 606. [CrossRef] [PubMed]
6. Abdullahi, Z.U.; Musa, S.S.; He, D.; Bello, U.M. Antiprotozoal effect of snake venoms and their fractions: A systematic review. *Pathogens* **2021**, *10*, 1632. [CrossRef]
7. Tasoulis, T.; Isbister, G.K. A review and database of snake venom proteomes. *Toxins* **2017**, *9*, 290. [CrossRef]
8. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, T.P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* **2009**, *6*, e1000097. [CrossRef]
9. Campbell, M.; McKenzie, J.E.; Sowden, A.; Katikireddi, S.V.; Brennan, S.E.; Ellis, S.; Hartmann-Boyce, J.; Ryan, R.; Shepperd, S.; Thomas, J.; et al. Synthesis without meta-analysis (SWiM) in systematic reviews: Reporting guideline. *BMJ* **2020**, *368*, l6890. [CrossRef] [PubMed]
10. Sudarshan, S.; Dhananjaya, B.L. Antibacterial activity of an acidic phospholipase A2 (NN-XIb-PLA₂) from the venom of *Naja naja* (Indian cobra). *SpringerPlus* **2016**, *5*, 112. [CrossRef]
11. Alves, R.d.C.; Vieira Júnior, J.R.; Freire, T.C.; Fonseca, A.S.; Sangi, S.C.; Barbieri, F.D.; Rocha, R.B.; Brito, L.G.; Pereira, S.D.; Luiz, M.B.; et al. Snake venoms and purified toxins as biotechnological tools to control *Ralstonia solanacearum*. *Pesq. Agropec. Bras.* **2020**, *55*, e01756. [CrossRef]

12. Vargas, L.J.; Londoño, M.; Quintana, J.C.; Rua, C.; Segura, C.; Lomonte, B.; Núñez, V. An acidic phospholipase A2 with antibacterial activity from Porthidium nasutum snake venom. *Comp. Biochem. Physiol. Part B Biochem. Mol. Biol.* **2012**, *161*, 341–347. [[CrossRef](#)] [[PubMed](#)]
13. Samy, R.P.; Gopalakrishnakone, P.; Bow, H.; Puspharaj, P.N.; Chow, V.T. Identification and characterization of a phospholipase A2 from the venom of the Saw-scaled viper: Novel bactericidal and membrane damaging activities. *Biochimie* **2010**, *92*, 1854–1866. [[CrossRef](#)] [[PubMed](#)]
14. Sudarshan, S.; Dhananjaya, B.L. The antimicrobial activity of an acidic phospholipase A2 (NN-XIa-PLA₂) from the venom of Najanajanaja (Indian Cobra). *Appl. Biochem.* **2015**, *176*, 2027–2038. [[CrossRef](#)] [[PubMed](#)]
15. Torres, A.F.; Dantas, R.T.; Toyama, M.H.; Diz Filho, E.; Zara, F.J.; de Queiroz, M.G.; Nogueira, N.A.; de Oliveira, M.R.; de Oliveira Toyama, D.; Monteiro, H.S.; et al. Antibacterial and antiparasitic effects of Bothropsmarajoensis venom and its fractions: Phospholipase A2 and L-amino acid oxidase. *Toxicon* **2010**, *55*, 795–804. [[CrossRef](#)]
16. Samy, R.P.; Kandasamy, M.; Gopalakrishnakone, P.; Stiles, B.G.; Rowan, E.G.; Becker, D.; Shanmugam, M.K.; Sethi, G. Chow V.T. Wound healing activity and mechanisms of action of an antibacterial protein from the venom of the eastern diamondback rattlesnake (*Crotalusadamanteus*). *PLoS ONE* **2014**, *9*, e80199. [[CrossRef](#)]
17. Jia, Y.; Villarreal, J. Phospholipases A2 purified from cottonmouth snake venoms display no antibacterial effect against four representative bacterial species. *Toxicon* **2018**, *151*, 1–4. [[CrossRef](#)]
18. Samy, R.P.; Gopalakrishnakone, P.; Ho, B.; Chow, V.T. Purification, characterization and bactericidal activities of basic phospholipase A2 from the venom of Agkistrodon halys (Chinese pallas). *Biochimie* **2008**, *90*, 1372–1388. [[CrossRef](#)]
19. Samy, R.P.; Pachiappan, A.; Gopalakrishnakone, P.; Thwin, M.M.; Hian, Y.E.; Chow, V.T.; Bow, H.; Weng, J.T. In vitro antimicrobial activity of natural toxins and animal venoms tested against Burkholderia pseudomallei. *BMC Infect. Dis.* **2006**, *6*, 100.
20. Samel, M.; Vija, H.; Kurvet, I.; Künnis-Beres, K.; Trummal, K.; Subbi, J.; Kahru, A.; Siigur, J. Interactions of PLA₂-s from Viperalebetina, Viperaberusberus and Najanajaoxiana venom with platelets, bacterial and cancer cells. *Toxins* **2013**, *5*, 203–223. [[CrossRef](#)]
21. Roberto, P.G.; Kashima, S.; Marcussi, S.; Pereira, J.O.; Astolfi-Filho, S.; Nomizo, A.; Giglio, J.R.; Fontes, M.R.; Soares, A.M.; França, S.C. Cloning and identification of a complete cDNA coding for a bactericidal and antitumoral acidic phospholipase A2 from Bothrops jararacussu venom. *Protein J.* **2004**, *23*, 273–285. [[CrossRef](#)]
22. Xu, C.; Ma, D.; Yu, H.; Li, Z.; Liang, J.; Lin, G.; Zhang, Y.; Lai, R. A bactericidal homodimeric phospholipases A2 from Bungarusfasciatus venom. *Peptides* **2007**, *28*, 969–973. [[CrossRef](#)] [[PubMed](#)]
23. Corrêa, E.A.; Kayano, A.M.; Diniz-Sousa, R.; Setúbal, S.S.; Zanchi, F.B.; Zuliani, J.P.; Matos, N.B.; Almeida, J.R.; Resende, L.M.; Marangoni, S.; et al. Isolation, structural and functional characterization of a new Lys49 phospholipase A2 homologue from Bothropsneuwiediiurutu with bactericidal potential. *Toxicon* **2016**, *115*, 13–21. [[CrossRef](#)] [[PubMed](#)]
24. Denegri, M.E.; Acosta, O.C.; Huancahuire-Vega, S.; Martins-de-Souza, D.; Marangoni, S.; Maruňak, S.L.; Teibler, G.P.; Leiva, L.C.; Ponce-Soto, L.A. Isolation and functional characterization of a new acidic PLA₂ Ba SpII RP4 of the Bothropsalternatus snake venom from Argentina. *Toxicon* **2010**, *56*, 64–74. [[CrossRef](#)]
25. Abid, I.; Jemel, I.; Alonazi, M.; Ben Bacha, A. A New Group II Phospholipase A2 from Walterinnesia aegyptia Venom with Antimicrobial, Antifungal, and Cytotoxic Potential. *Processes* **2020**, *8*, 1560. [[CrossRef](#)]
26. Barbosa, P.S.; Martins, A.M.; Havt, A.; Toyama, D.O.; Evangelista, J.S.; Ferreira, D.P.; Joazeiro, P.P.; Beriam, L.O.; Toyama, M.H.; Fonteles, M.C.; et al. Renal and antibacterial effects induced by myotoxin I and II isolated from Bothrops jararacussu venom. *Toxicon* **2005**, *46*, 376–386. [[CrossRef](#)] [[PubMed](#)]
27. Shebl, R.I.; Mohamed, A.F.; Ali, A.E.; Amin, M.A. Antimicrobial profile of selected snake venoms and their associated enzymatic activities. *Br. Microbiol Res. J.* **2012**, *2*, 251–263. [[CrossRef](#)]
28. Almeida, J.R.; Lancellotti, M.; Soares, A.M.; Calderón, L.A.; Ramírez, D.; González, W.; Marangoni, S.; Da Silva, S.L. CoaTx-II, a new dimeric Lys49 phospholipase A2 from Crotalus oreganus abyssus snake venom with bactericidal potential: Insights into its structure and biological roles. *Toxicon* **2016**, *120*, 147–158. [[CrossRef](#)]
29. Toyama, M.H.; de Oliveira, D.G.; Beriam, L.O.; Novello, J.C.; Rodrigues-Simioni, L.; Marangoni, S. Structural, enzymatic and biological properties of new PLA₂ isoform from Crotalusdurissusterrificus venom. *Toxicon* **2003**, *41*, 1033–1038. [[CrossRef](#)]
30. Bacha, A.B.; Alonazi, M.A.; Elshikh, M.S.; Karray, A. A novel bactericidal homodimeric PLA₂ group-I from Walterinnesiaegyptia venom. *Int. J. Biol. Macromol.* **2018**, *117*, 1140–1146. [[CrossRef](#)]
31. Santamaría, C.; Larios, S.; Quirós, S.; Pizarro-Cerda, J.; Gorvel, J.P.; Lomonte, B.; Moreno, E. Bactericidal and antiendotoxic properties of short cationic peptides derived from a snake venom Lys49 phospholipase A2. *Antimicrob. Agents Chemother.* **2005**, *49*, 1340–1345. [[CrossRef](#)]
32. Costa, T.R.; Menaldo, D.L.; Oliveira, C.Z.; Santos-Filho, N.A.; Teixeira, S.S.; Nomizo, A.; Fuly, A.L.; Monteiro, M.C.; de Souza, B.M.; Palma, M.S.; et al. Myotoxic phospholipases A2 isolated from Bothropsbrazili snake venom and synthetic peptides derived from their C-terminal region: Cytotoxic effect on microorganism and tumor cells. *Peptides* **2008**, *29*, 1645–1656. [[CrossRef](#)] [[PubMed](#)]
33. Nevalainen, T.J.; Graham, G.G.; Scott, K.F. Antibacterial actions of secreted phospholipases A2. Review. *Biochim. et Biophys. Acta (BBA)-Mol. Cell Biol. Lipids* **2008**, *1781*, 1–9. [[CrossRef](#)] [[PubMed](#)]
34. Andrews, J.M. Determination of minimum inhibitory concentrations. *J. Antimicrob. Chemother.* **2001**, *48* (Suppl. S1), 5–16. [[CrossRef](#)]

35. Parvekar, P.; Palaskar, J.; Metgud, S.; Maria, R.; Dutta, S. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of silver nanoparticles against *Staphylococcus aureus*. *Biomater. Investig. Dent.* **2020**, *7*, 105–109. [PubMed]
36. Barlow, A.; Pook, C.E.; Harrison, R.A.; Wüster, W. Coevolution of diet and prey-specific venom activity supports the role of selection in snake venom evolution. *Proc. R. Soc. B Biol. Sci.* **2009**, *276*, 2443–2449. [CrossRef]
37. Creer, S.; Malhotra, A.; Thorpe, R.S.; Stöcklin, R.S.; Favreau, P.S.; Hao Chou, W.S. Genetic and ecological correlates of intraspecific variation in pitviper venom composition detected using matrix-assisted laser desorption time-of-flight mass spectrometry (MALDI-TOF-MS) and isoelectric focusing. *J. Mol. Evol.* **2003**, *56*, 317–329. [CrossRef] [PubMed]
38. Fry, B.G.; Sunagar, K.; Casewell, N.R.; Kochva, E.; Roelants, K.; Scheib, H.; Wüster, W.; Vidal, N.; Young, B.; Burbrink, F.; et al. The origin and evolution of the Toxicofera reptile venom system. In *Venomous Reptiles and Their Toxins: Evolution, Pathophysiology and Biodiscovery*; Fry, B.G., Ed.; Oxford University Press: Oxford, UK, 2015; Volume 2015, pp. 1–31.
39. Miller, R.A.; Jian, J.; Beno, S.M.; Wiedmann, M.; Kovac, J. Intraclade variability in toxin production and cytotoxicity of *Bacillus cereus* group type strains and dairy-associated isolates. *Appl. Environ. Microbiol.* **2018**, *84*, e02479-17. [CrossRef] [PubMed]
40. Nikpour, S.; Tabatabaie, F.; Sharifi, I.; Mostafavi, M.; Oliaee, R.T.; Sharifi, F.; Babaei, Z.; Jafari, E.; Salarkia, E.; Shahbazzadeh, D. The fraction of the snake venom, its leishmanicidal effect, and the stimulation of an anti-leishmania response in infected macrophages. *Endocr. Metab. Immune Disord. -Drug Targets* **2021**, *21*, 1115–1124. [CrossRef]
41. Harris, J.B.; Scott-Davey, T. Secreted phospholipases A2 of snake venoms: Effects on the peripheral neuromuscular system with comments on the role of phospholipases A2 in disorders of the CNS and their uses in industry. *Toxins* **2013**, *5*, 2533–2571. [CrossRef]
42. Deshwal, A.; Phan, P.; Datta, J.; Kannan, R.; Thallapuram, S.K. A Meta-Analysis of the Protein Components in Rattlesnake Venom. *Toxins* **2021**, *13*, 372. [CrossRef]
43. Mora-Obando, D.; Fernandez, J.; Montecucco, C.; Gutiérrez, J.M.; Lomonte, B. Synergism between basic Asp49 and Lys49 phospholipase A2 myotoxins of viperid snake venom in vitro and in vivo. *PLoS ONE* **2014**, *9*, e109846. [CrossRef] [PubMed]
44. Oliveira, L.A.; Ferreira, R.S.; Barraviera, B.; Carvalho, F.C.; Barros, L.C.; Santos, L.D.; Pimenta, D.C. *Crotalus durissus terrificus* crotapotinnaturally displays preferred positions for aminoacid substitutions. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **2017**, *23*, 46. [CrossRef] [PubMed]
45. da Silva Lomeo, R.; de Faria Gonçalves, A.P.; da Silva, C.N.; de Paula, A.T.; Santos, D.O.; Fortes-Dias, C.L.; Gomes, D.A.; de Lima, M.E. Crotoxin from *Crotalus durissus terrificus* snake venom induces the release of glutamate from cerebrocortical synaptosomes via N and P/Q calcium channels. *Toxicon* **2014**, *85*, 5–16. [CrossRef] [PubMed]
46. Sudharshan, S.; Dhananjaya, B.L. Antibacterial potential of a basic phospholipase A2 (VRV-PL-VIIIa) from *Daboia russelii pulchella* (Russell's viper) venom. *J. Venom. Anim. Toxins Incl. Trop. Dis.* **2015**, *21*, 1–8. [CrossRef] [PubMed]
47. Taylor, T.A.; Unakal, C.G. *Staphylococcus aureus*. Stat Pearls. 2022. Available online: <https://www.ncbi.nlm.nih.gov/books/NBK441868> (accessed on 18 July 2022).
48. Samy, R.P.; Gopalakrishnakone, P.; Stiles, B.G.; Girish, K.S.; Swamy, S.N.; Hemshekhar, M.; Tan, K.S.; Rowan, E.G.; Sethi, G.; Chow, V.T.K. Snake venom phospholipases A2: A novel tool against bacterial diseases. *Curr. Med. Chem.* **2012**, *19*, 6150–6162. [CrossRef]
49. Jami, A.A.; Fathi, B.; Jamshidi, A.; Zolfagharian, H.; Zare, M.A. Investigation of the antibacterial effect of venom of the Iranian snake *Echiscarinatus*. *Iran. J. Vet. Sci Technol.* **2010**, *2*, 93–100.
50. Mestrovic, T.; Aguilar, G.R.; Swetschinski, L.R.; Ikuta, K.S.; Gray, A.P.; Weaver, N.D.; Han, C.; Wool, E.E.; Hayoon, A.G.; Hay, S.I.; et al. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: A cross-country systematic analysis. *Lancet Public Health* **2022**, *7*, e897–e913. [CrossRef]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.